New Therapeutic Strategy Against Preeclampsia: Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1

Assistance Publique - Hôpitaux de Paris1 个研究点分布在 1 个国家目标入组 236 人2017年6月12日

适应症Preeclampsia

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: Preeclampsia
发起方: Assistance Publique - Hôpitaux de Paris
入组人数: 236
试验地点: 1
主要终点: ratio sFlt-1/PlGF
状态: 已完成
最后更新: 上个月

概览研究者入排标准结局指标研究点相似试验

概览

简要总结

The aim of the study is to setup a collection of maternal plasma and serum from patients with preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1

详细描述

A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP) : * Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP * Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP * Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP * Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP * Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP

注册库

clinicaltrials.gov

开始日期

2017年6月12日

结束日期

2019年6月12日

最后更新

上个月

研究类型

Observational

性别

Female